Serum visfatin level as a prognostic marker in colorectal cancer patients: A retrospective cohort study

[1]  J. M. Gutiérrez-Valverde,et al.  Environmental factors and awareness of colorectal cancer in people at familial risk , 2019, Revista latino-americana de enfermagem.

[2]  Xiaofei Yan,et al.  Visfatin mediates doxorubicin resistance in human colorectal cancer cells via up regulation of multidrug resistance 1 (MDR1) , 2017, Cancer Chemotherapy and Pharmacology.

[3]  P. Cohen,et al.  Insights into the Link Between Obesity and Cancer , 2017, Current Obesity Reports.

[4]  E. Świętochowska,et al.  Chemotherapy and plasma adipokines level in patients with colorectal cancer. , 2017, Postepy higieny i medycyny doswiadczalnej.

[5]  W. Fan,et al.  Circulating Resistin Levels and Risk of Colorectal Cancer: A Meta-Analysis , 2016, BioMed research international.

[6]  Ahmedin Jemal,et al.  Global patterns and trends in colorectal cancer incidence and mortality , 2016, Gut.

[7]  Lingyun Zhang,et al.  Regulative Effect of Nampt on Tumor Progression and Cell Viability in Human Colorectal Cancer , 2015, Journal of Cancer.

[8]  A. Gamian,et al.  Nampt/PBEF/Visfatin Upregulation in Colorectal Tumors, Mirrored in Normal Tissue and Whole Blood of Colorectal Cancer Patients, Is Associated with Metastasis, Hypoxia, IL1β, and Anemia , 2015, BioMed research international.

[9]  Min-Ming Xia,et al.  Elevated plasma visfatin levels correlate with poor prognosis of gastric cancer patients , 2014, Peptides.

[10]  Johanna W Lampe,et al.  Long-Chain Omega-3 Polyunsaturated Fatty Acid Intake and Risk of Colorectal Cancer , 2014, Nutrition and cancer.

[11]  L. Šenolt,et al.  Early changes in serum visfatin after abdominal surgery: a new pro-inflammatory marker in diagnosis? , 2014, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[12]  M. Hedayati,et al.  Resistin Effect on HCT-116 Colorectal Cancer Cells Proliferation and Telomer- ase Expression , 2014 .

[13]  G. De Pergola,et al.  Obesity as a Major Risk Factor for Cancer , 2013, Journal of obesity.

[14]  T. Rohan,et al.  Visfatin, a potential biomarker and prognostic factor for endometrial cancer. , 2013, Gynecologic oncology.

[15]  Eun Sook Kim,et al.  Visfatin stimulates proliferation of MCF-7 human breast cancer cells , 2010, Molecules and cells.

[16]  T. Matsuda,et al.  Adipocytokines as new promising markers of colorectal tumors: Adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer , 2010, Cancer science.

[17]  H. Randeva,et al.  Obesity and prostate cancer: a role for adipokines. , 2007, European urology.

[18]  R. Busse,et al.  Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin , 2006, Diabetologia.

[19]  M. Fasshauer,et al.  Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. , 2005, Diabetes.

[20]  A. Vidal-Puig,et al.  Visfatin: the missing link between intra-abdominal obesity and diabetes? , 2005, Trends in molecular medicine.

[21]  M. Matsuda,et al.  Visfatin: A Protein Secreted by Visceral Fat That Mimics the Effects of Insulin , 2005, Science.

[22]  I McNiece,et al.  Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor , 1994, Molecular and cellular biology.

[23]  R. Gebhardt,et al.  Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. , 2010, Biochemical and biophysical research communications.

[24]  J. Flier,et al.  0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(6):2548–2556 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2004-0395 , 2022 .